Xencor Inc. Common Stock (XNCR)
Stock · NASDAQ · Health Care
$22.85as of 10/16/2026
Price chart
Active signals
XNCR Signal Track Record
How signals performed across all stocks →What XNCR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | -1.8% | 40% | September 15, 2026 |
| Bollinger Band Breakout | 26 | -1.1% | 42% | August 18, 2026 |
| 200-Day Moving Average TouchActive now | 21 | +0.5% | 52% | June 17, 2026 |
| Bollinger Band BreakdownActive now | 20 | -2.0% | 45% | May 15, 2026 |
| Any 20-session window (baseline) | -1.0% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About XNCR
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffus…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 260
- Website
- xencor.com/
Fundamentals
- 1-day range
- $22.76$24.21
- Market cap
- $1.48B
- P/E (trailing)
- —
- P/E (forward)
- -6.46
- EPS (trailing)
- $-2.17
- Dividend yield
- —
- Beta
- 0.81
- Avg. volume
- 1.37M
How Xencor Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Xencor Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- XNCRXencor Inc. Common Stock$22.85▼ 4.79%Market cap $1.48BP/E —$10.38$30.61
- HROWHarrow Inc. Common Stock$27.28▼ 5.11%Market cap $1.49BP/E —$26.96$54.85
- AVBPArriVent BioPharma Inc. Common Stock$16.66▼ 0.77%Market cap $1.44BP/E —$11.36$35.83
- PAHCPhibro Animal Health Corporation Class A Common Stock$38.82▲ 2.21%Market cap $1.44BP/E 15.44$28.25$60.08
- INVAInnoviva Inc. Common Stock$20.78▼ 0.38%Market cap $1.56BP/E 4.25$16.52$25.15
- TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$34.46▼ 4.38%Market cap $1.58BP/E —$14.72$49.91
- LBRXLB Pharmaceuticals Inc Common Stock$36.74▲ 0.14%Market cap $1.38BP/E —$14.32$50.16
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| XNCR Xencor Inc. Common Stock | $1.48B | — | $22.85 | ▼ 4.79% | $10.38$30.61 |
| HROW Harrow Inc. Common Stock | $1.49B | — | $27.28 | ▼ 5.11% | $26.96$54.85 |
| AVBP ArriVent BioPharma Inc. Common Stock | $1.44B | — | $16.66 | ▼ 0.77% | $11.36$35.83 |
| PAHC Phibro Animal Health Corporation Class A Common Stock | $1.44B | 15.44 | $38.82 | ▲ 2.21% | $28.25$60.08 |
| INVA Innoviva Inc. Common Stock | $1.56B | 4.25 | $20.78 | ▼ 0.38% | $16.52$25.15 |
| TRAX First Tracks Biotherapeutics Inc. Ordinary Shares | $1.58B | — | $34.46 | ▼ 4.38% | $14.72$49.91 |
| LBRX LB Pharmaceuticals Inc Common Stock | $1.38B | — | $36.74 | ▲ 0.14% | $14.32$50.16 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Ellen Feigal · June 18, 2026 · Sale6.8K @ $13.06
- Raymond Joseph Deshaies · June 16, 2026 · Grant20.6K
- Raymond Joseph Deshaies · June 16, 2026 · Grant10.3K
- Ellen Feigal · June 16, 2026 · Grant20.6K
- Ellen Feigal · June 16, 2026 · Grant10.3K
- Barbara Klencke · June 16, 2026 · Grant20.6K
- Barbara Klencke · June 16, 2026 · Grant10.3K
- Kurt A. Gustafson · June 16, 2026 · Grant20.6K
- Kurt A. Gustafson · June 16, 2026 · Grant10.3K
- Alan Bruce Montgomery · June 16, 2026 · Grant20.6K
- Alan Bruce Montgomery · June 16, 2026 · Grant10.3K
- Richard J. Ranieri · June 16, 2026 · Grant20.6K
- Richard J. Ranieri · June 16, 2026 · Grant10.3K
- Todd E. Simpson · June 16, 2026 · Grant20.6K
- Todd E. Simpson · June 16, 2026 · Grant10.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 80.06M
- Total value held
- $935.92M
- Institutional holders
- 194
- Unknown13.04M
- Unknown10.34M
- Unknown7.13M
- Unknown6.78M
- Unknown4.90M
- Unknown4.35M
- Unknown3.10M
- Unknown2.45M
- Unknown2.18M
- Unknown1.82M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
XNCR: Improved Funding for Obexelimab
Xencor announced that it has secured better funding for its experimental antibody Obexelimab, which could support further development of the therapy. The news comes as the stock is near its 18‑touch support level of $12 and still below the 52‑week low of $10.38. Analysts maintain a target of $31.42, indicating that the funding may help the company move toward that goal.
XNCR: Improved Funding for Obexelimab. Xencor announced that it has secured better funding for its experimental antibody Obexelimab, which could support further development of the therapy. The news comes as the stock is near its 18‑touch support level of $12 and still below the 52‑week low of $10.38. Analysts maintain a target of $31.42, indicating that the funding may help the company move toward that goal.